This has direct therapeutic relevance, especially considering the recent DESTINY-Breast04, in which a new category of breast cancer patients, HER2-low, had PFS and OS meaningfully improved by use of trastuzumab deruxtecan (TDxd)81, leading to FDA approval for use of TDxd for this indication. Here, ERBB2 is linked to breast cancer.